The mechanism of accumulation of tumour-localising radiopharmaceuticals

European Journal of Nuclear Medicine

Volumn 25, Issue 3, 1998, Pages 277-305

  Pauwels, Ernest K J ^a   McCready, V Ralph ^b   Stoot, Jan H M B ^a,b   Van Deurzen, Derek F P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 67; GLUCOSE; GLUCOSE TRANSPORTER; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TETROFOSMIN; THALLIUM 201;

DIAGNOSTIC IMAGING; DRUG ACCUMULATION; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; METABOLISM; NUCLEAR MEDICINE; REVIEW; TUMOR GROWTH; TUMOR LOCALIZATION;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RADIOPHARMACEUTICALS;

EID: 0031944876     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050229     Document Type: Review

References (301)

1. Chan S, Sikora K. The potentional of oncogene products as tumour markers. Cancer Surv 1987; 6: 185-207.
2. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-646.
3. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
4. 99mTc-methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997; 27: 40-54.
5. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-297.
6. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306: 239-242.
7. Bishop JM. The molecular genetics of cancer. Science 1987; 235: 305-311.
8. Kurman RJ, Jenson AB, Lancaster WD. Papillomavirus infection of the cervix. II. Relationship to intraepithelial neoplasia based on the presence of specific viral structural proteins. Am J Surg Pathol 1983; 7: 39-52.
9. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-495.
10. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831-840.
11. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-141.
12. 125I]iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 1996; 37 (4 Suppl): 25s-29s.
13. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974; 355: 77-104.
14. Miller WR, Ellis IO, Sainsbury JR, Dixon JM. ABC of breast diseases. Prognostic factors. BMJ 1994; 309: 1573-1576.
15. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
16. Urban JL, Scheiber H. Tumor antigens. Annu Rev Immunol 1992; 10: 617-644.
17. Moffat FL, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the 1MMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol 1996; 14: 2295-2305.
18. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur Nucl Med 1995; 22: 265-280.
19. De Bie SH, Ferreira TC, Pauwels EKJ, Cleton FJ. Immunoscintigraphy for cancer detection: "A thousand ills require a thousant cures". J Cancer Res Clin Oncol 1992; 118: 1-15.
20. Warburg O. Uber den Stoffwechsel der Carcinomzelle. Klin Wochenschr Berl 1925; 4: 534-536 (Also translated J Cancer Res. Lancaster, Pa., 1924-1925: 148-163).
21. Warburg O. Uber den Stoffwechsel der Carcinomzelle. Klin Wochenschr Berl 1925; 4: 534-536 (Also translated J Cancer Res. Lancaster, Pa., 1924-1925: 148-163).
22. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
23. Martineau R, Kohlbacher M, Shaw SN, Amos H. Enhancement of hexose entry into chick fibroblasts by starvation: differential effect on galactose and glucose. Proc Natl Acad Sci U S A 1972; 69: 3407-3411.
24. Salter DW, Baldwin SA, Lienhard GE, Weber MJ. Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1982; 79: 1540-1544.
25. Shawver LK, Olson SA, White MK, Weber MJ. Degradation and biosynthesis of the glucose transporter protein in chicken embryo fibroblasts transformed by the src oncogene. Mol Cell Biol 1987; 7: 2112-2118.
26. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988; 263: 13655-13662.
27. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492-1495.
28. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219: 713-725.
29. Murakami T, Nishiyama T, Shirotani T, et al. Type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem 1992; 267: 9300-9306.
30. Su T-S, Tsai T-F, Chi C-W, Han S-H, Chou C-K. Elevation of facilitated glucose transporter messenger RNA in human hepatocellular carcinoma. Hepatology 1990; 11: 118-122.
31. Nishioka T, Oda Y, Seino Y, et al. Distribution of glucose transporters in human brain tumors. Cancer Res 1992; 52: 3972-3979.
32. Monakhov NK, Neistadt EL, Shavlovskii MM, Shartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978; 61: 27-33.
33. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256: 8699-8704.
34. Parry DM, Pedersen PL. Intracellular localisation and properties of particulate hexokinase in the Novikoff ascites tumor. J Biol Chem 1983; 258: 101904-101912.
35. Arora KK, Fancuilli M, Pedersen PL. Glucose phosphorylation in tumor cells. Cloning, sequencing, and overexpression in active form of a full-length cDNA encoding a mitochondrial bindable form of hexokinase. J Biol Chem 1990; 265: 6481-6488.
36. Fanciulli M, Paggi MG, Btuno T, et al. Glycolysis and growth rate in normal and in hexokinase transfected NIH 3T3 cells. Oncol Res 1994; 6: 405-409.
37. Renner ED, Plagemann PGW, Bernlohr RW. Permeation of glucose by simple and facilitated difusion by Novicoff rat hepatoma cells in suspension culture and its relationship to glucose metabolism. J Biol Chem 1972; 247: 5765-5776.
38. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18-F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-1161.
39. Sokoloff L, Reivich M, Kennedy C, et al. The [14-C]deoxy glucose method for the measurement of local cerebral glucose utilisation: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
40. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675.
41. 18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-889.
42. 18F]-fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133-1137.
43. Lindholm P, Minn H, Leskinnen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34: 1-6.
44. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
45. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
46. Bretscher MS. The molecules of the cell membrane. Sci Am 1985; 253: 100-108.
47. Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987; 56: 615-649.
48. Berridge MJ. The molecular basis of communication within the cell. Sci Am 1985; 253: 142-152.
49. Schramm M, Selinger Z. Message transmission: receptor controlled adenylate cyclase system. Science 1984; 225: 1350-1356.
50. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79.
51. Noe BD, Spiess J. Evidence for biosynthesis and differential post-translational proteolytic processing of different (pre)prosomatostatins in pancreatic islets. J Biol Chem 1983; 258: 1121-1128.
52. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-1501.
53. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1556-1563.
54. Reubi JC. Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med 1992; 65: 493-503; discussion 531-536.
55. Robbins RJ. Somatostatin and cancer. Metabolism 1996; 45 (8 Suppl 1): 98-100.
56. Burbach JP, Meijer OC. The structure of neuropeptide receptors. Eur J Pharmacol 1992; 227: 1-18.
57. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993; 16: 34-38.
58. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994; 198: 605-612.
59. + channels through protein dephosphorylation. Nature 1991; 351: 570-573.
60. Reubi JC, Kvols L, Krenning E, Lamberts SW. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990 (9 Suppl 2); 39: 78-81.
61. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992; 89: 251-255.
62. AM OC, Raynor K, Lolait SJ, Reisine T. Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol 1994; 46: 291-298.
63. Bell GI, Yasuda K, Kong H, Law SF, Raynor K, Reisine T. Molecular biology of somatostatin receptors. Ciba Found Symp 1995; 190: 65-79.
64. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70: 530-537.
65. Patel YC, Greenwood M, Panetta R, et al. Molecular biology of somatostatin receptor subtypes. Metabolism 1996; 45 (8 Suppl 1): 31-38.
66. Valkema R, Steens J, Cleton FJ, Pauwels EKJ. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 1996; 122: 513-532.
67. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
68. Foekens JA, van Putten WL, Portengen H, et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 1990; 37: 815-821.
69. Cerra M, Cecco L, Montella M, Tucillo F, Bonelli P, Botti G. Epidermal growth factor receptor in human breast cancer: comparison with steriod receptors and other prognostic factors. Int J Biol Markers 1995; 10: 136-142.
70. Lamberts SW, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-287.
71. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A 1986; 83: 1896-1900.
72. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140.
73. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31: 1501-1509.
74. Bakker WH, Krenning EP, Breeman WA, et al. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man [published erratum appears in J Nucl Med 1991; 32:1999] [see comments]. J Nucl Med 1991; 32: 1184-1189.
75. 111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-1591.
76. 111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49: 1593-1601.
77. 111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
78. 123I-Tyr3]octreotide. Eur J Nucl Med 1993; 20: 1089-1094.
79. 111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 1994; 21: 328-335.
80. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 1996; 45 (8 Suppl 1): 17-20.
81. Moreau JP, Kim S, Dong JZ, et al. Improved analogs and novel delivery systems for somatostatin octapeptides. Metabolism 1996; 45 (8 Suppl 1): 24-26.
82. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994; 54: 690-700.
83. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36: 1846-1853.
84. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
85. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
86. 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol 1996; 23: 503-507.
87. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
88. Raderer M, Becherer A, Kurtaran A, et al. Comparison of iodine- 123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med 1996; 37: 1480-1487.
89. 125I]VMEME). Int J Rad Appl Instrum [B] 1988; 15: 327-332.
90. 11C-toremifene in rats bearing DMBA-induced mammary carcinoma. Pharmacol Toxicol 1989; 64: 373-377.
91. 125I]iodo-19-norpregna1,3,5-(10),20-tetraene-3,17-diols. J Med Chem 1991; 34: 854-860.
92. 123I]iodovinyloestradiol and its 11β-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats. Eur J Nucl Med 1996; 23: 295-307.
93. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995; 61: 786-792.
94. 1]substance P. J Nucl Med 1996; 37: 108-117.
95. McAfee JG, Neumann RD. Radiolabeled peptides and other ligands tor receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol 1996; 23: 673-676.
96. Moody TW, Carney DN, Cuttitta F, Quattrocchi K, Minna JD. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci 1985; 37: 105-113.
97. Halmos G, Pinski J, Szoke B, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett 1994; 85: 111-118.
98. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644-647.
99. Chicone L, Narayan S, Townsend CM Jr, Singh P. The presence of a 33-40 kDa gastrin binding protein on human and mouse colon cancer. Biochem Biophys Res Commun 1989; 164: 512-519.
100. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386.
101. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 1994; 74: 2555-2561.
102. Imai A, Ohno T, Ohsuye K, Tamaya T. Expression of gonadotropin-releasing hormone receptor in human epithelial ovarian carcinoma. Ann Clin Biochem 1994; 31: 550-555.
103. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994; 55: 144-148.
104. Eberle AN, Siegrist W, Bagutti C, et al. Receptors for melanocyte-stimulating hormone on melanoma cells. Ann N Y Acad Sci 1993; 680: 320-341.
105. 111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int J Cancer 1994; 58: 749-755.
106. Neal DE, Smith K, Fennelly JA, Bennett MK, Hall RR, Harris AL. Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. J Urol 1989; 141: 517-521.
107. Giaid A, Hamid QA, Springall DR, et al. Detection of endothelin immunoreactivity and mRNA in pulmonary tumours. J Pathol 1990; 162: 15-22.
108. Kubota K, Ishiwata K, Kubota R, et al. Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-L-methionine. J Nucl Med 1996; 37: 320-325.
109. Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 1959; 19: 1030-1039.
110. Foster DO, Pardee AB. Transport of amino acid by confluent and nonconfluent 3T3 and polyoma virus-transformed 3T3 cells growing on glass cover slips. J Biol Chem 1969; 244: 2675-2681.
111. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-α-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996; 23: 1345-1353.
112. Knapp WH, Helus F, Layer K, Panzer M, Hover KH, Ostertag H. Nitrogen-13 glutamate uptake and perfusion in Walker 256 carcinosarcoma before and after single-dose irradiation. J Nucl Med 1986; 27: 1604-1610.
113. 11C]tyrosine and fluorine-18-fluorodeoxyglucose. J Nucl Med 1992; 33: 373-379.
114. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-492.
115. Nickerson M, Collier B. Drugs inhibiting adrenergic nerves and structures innervated by them. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics, 5th edn. New York: Macmillan; 1975: 553-564.
116. Short JH, Darby TD. Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. J Med Chem 1967; 10: 833-840.
117. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21: 561-581.
118. 131I-meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 1985; 15: 154-160.
119. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994; 21: 545-559.
120. 131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
121. 123I]iodobenzylguanidine: concise communication. J Nucl Med 1984; 25: 436-440.
122. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 1984; 25: 773-775.
123. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med 1990; 16: 325-335.
124. Sinzinger H, Renner F, Granegger S. Unsuccessful iodine-131 MIBG imaging of carcinoid tumors and apudomas [letter]. J Nucl Med 1986; 27: 1221-1222.
125. 123I metaiodobenzylguanidine (MIBG) scintigraphy of retinoblastoma: preliminary experience. Br J Ophthalmol 1989; 73: 146-150.
126. 131I-metaiodobenzylguanidine (mIBG) for bronchial oat cell cancer and melanoma detection? Eur J Nucl Med 1989; 15: 629-631.
127. Voute PA, de Kraker J, Hoefnagel CA. Tumours of the sympathetic nervous system: neuroblastoma, ganglioneuroma and phaeochromocytoma. In: Voute PA, Barrett A, Lemerle J, eds. Cancer in children. Clinical Management. Berlin Heidelberg New York: Springer; 1992: 226-243.
128. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305: 12-17.
129. Jaques S, Jr., Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984; 26: 539-546.
130. Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med 1997; 38: 49-52.
131. Gils van APG, Erkel van AR, Falke THM, Pauwels EKJ. Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Eur J Nucl Med 1994; 21: 239-253.
132. Gasnier B, Roisen MP, Scherman D, Coornaert S, Desplanones G, Henry JP. Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 1985; 29: 275-280.
133. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993; 34: 1140-1146.
134. Troncone L. Radiolabelled metaiodobenzylguanidine in the diagnosis of neural crest tumours. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. London: Churchill Livingstone; 1994:745-756.
135. Giordano A, Calcagni ML, Rossi B, et al. Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. Eur J Nucl Med 1997; 24: 52-58.
136. 123I-MIBG pulmonary removal: a biochemical marker of minimal lung endothelial cell lesions. Eur J Nucl Med 1990; 16: 633-637.
137. Bruno S, Poster DS, Bono VH Jr, Macdonald JS, Kubota TT. "High-dose" thymidine in clinical oncology. Cancer Treat Rep 1981; 65: 57-63.
138. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988; 6: 871-879.
139. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990; 18: 1393-1398.
140. Watanabe KA, Su TL, Klein RS, et al, Nucleosides, 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships. J Med Chem 1983; 26: 152-156.
141. Kufe DW, Egan EM, Rosowsky A, Ensminger W, Frei E. Thymidine arrest and synchrony of cellular growth in vivo. Cancer Treat Rep 1980; 64: 1307-1317.
142. Foulon CF, Zhang YZ, Adelstein SJ, Kassis AI. Instantaneous preparation of radiolabeled 5-iodo-2′-deoxyuridine. Appl Radiat Isot 1995; 46: 1039-1046.
143. O'Donoghue JA. Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med 1996; 37 (4 Suppl): 3s-6s.
144. 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol Relat Stud Phys Chem Med 1975; 28: 225-241.
145. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6 [published erratum appears in Med Phys 1995; 22: 1837]. Med Phys 1994; 21: 1901-1915.
146. Kassis AI, Howell RW, Sastry KSR, Adelstein SJ. Positional effects of Auger decays in mammalian cells in culture. In: Baverstock KF, Charlton DE, eds. DNA damage by Auger emitters. London: Taylor & Francis; 1988:1-13.
147. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991; 21: 1541-1551.
148. 125I-iodo-2′-deoxyuridine for cancer diagnosis and therapy. J Nucl Med Allied Sci 1990; 34: 299-303.
149. 125I]iodo-2′-deoxyuridine injected intratumorally in patients with breast cancer. Ann N Y Acad Sci 1993; 698: 204-211.
150. 125I]iodo-2′-deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med 1996; 37 (4 Suppl): 16s-19s.
151. 125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med 1993; 34: 1175-1183.
152. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med 1996; 37 (4 Suppl): 22s-25s.
153. Sarosdy MF. Principles of intravesical chemotherapy and immunotherapy. Urol Clin North Am 1992; 19: 509-519.
154. Britton KE, Granowska M. Tumour identification using radiopharmaceuticals. Clin Radiol 1997; 52: 731-738.
155. Jones AG, Abrams MJ, Davison A, et al. Biological studies of a new class of technetium complexes: the hexakis(alkyl-isonitrile)technetium(I) cations. Int J Nucl Med Biol 1984; 11: 225-234.
156. Holman BL, Sporn V, Jones AG, et al. Myocardial imaging with technetium-99m CPl: initial experience in the human. J Nucl Med 1987; 28: 13-18.
157. Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301-311.
158. Muller S, Guth-Tougelidis B, Creutzig H. Imaging of malignant tumors with Tc-99m-MIBI SPECT [abstract]. J Nucl Med 1987; 28: 562.
159. Muller SP, Reiners C, Paas M, et al. Tc-99m MIBI and Tl-201 uptake in bronchial carcinoma [abstract]. J Nucl Med 1989; 30: 845.
160. Mousa SA, Williams SJ, Sands H. Characterization of in vivo chemistry of cations in the heart. J Nucl Med 1987; 28: 1351-1357.
161. Mousa SA, Maina M, Brown BA, Williams SJ. Retention of RP-30 in the heart may be due to binding to a cytosolic protein [abstract]. J Nucl Med 1987; 28: 619.
162. Chin ML, Carvalho P, Kronauge JF, Holman BL, Jones AG, Piwnica-Worms D. Mitochondrial associated Tc-MIBI in perfused rat heart: pitfalls of tissue fractionation [abstract]. J Nucl Med 1990; 31: 832.
163. Sands H, Delano ML, Gallagher BM. Uptake of hexakis(t-butylisonitrile) technetium (I) and hexakis(isopropylisonitrile) technetium (I) by neonatal rat myocytes and human erythrocytes. J Nucl Med 1986; 27: 404-408.
164. Piwnica-Worms D, Kronauge JF, Holman BL, Lister-James J, Davison A, Jones AG. Hexakis (carhomethoxy isopropyl isonitrile) technetium (1). a new myocardial perfusion agent: binding characteristics in cultured chick heart cells. J Nucl Med 1988; 29: 55-61.
165. 99mTc-sestamibi in oncology. Tumori 1996; 82: 12-21.
166. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2198-2202.
167. Crane P, Laliberte R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20-25.
168. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
169. Piwnica-Worms D, Kronauge JF, Davison A, et al. Mitochondrial localisation of Tc-MIBI in cultured chick heart cells by electron probe x-ray analysis (EPXMA) [abstract]. J Nucl Med 1990; 31: 748.
170. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1522.
171. Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells. J Nucl Med 1990; 31: 464-472.
172. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
173. Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 1988; 80: 14-20.
174. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
175. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16: 156-165.
176. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-199.
177. Piwnica-Worms D, Chiu ML, Croop JM. Enhancement of Tc-99m-SestaMIBI accumulation in multidrug resistant (MDR) cells by cytotoxic drugs and MDR reversing agents. J Nucl Med 1993; 34: 140p.
178. Jones S, Hendel RC. Technetium-99m tetrofosmin: a new myocardial perfusion agent. J Nucl Med Technol 1993; 21: 191-195.
179. Cuocolo A, Soricelli A, Nicolai E, et al. Technetium-99m-tetrofosmin regional myocardial uptake at rest: relation to severity of coronary artery stenosis in previous myocardial infarction. J Nucl Med 1995; 36: 907-913.
180. m-tetrofosmin (Myoview): a preliminary report. Nucl Med Commun 1995; 16: 694-697.
181. Basoglu T, Sahin M, Coskun C, Koparan A, Bernay I, Erkan L. Technetium-99m-tetrofosmin uptake in malignant lung tumours. Eur J Nucl Med 1995; 22: 687-689.
182. Klain M, Maurea S, Lastoria S, Cuocolo A, Colao A, Salvatore M. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 1995; 36: 2248-2251.
183. Kosuda S, Yokoyama H, Katayama M, Yokokawa T, Kusano S, Yamamoto O. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1995; 22: 1218-1220.
184. Rambaldi PF, Mansi L, Procaccini E, Di Gregorio F, Del Vecchio E. Breast cancer detection with Tc-99m tetrofosmin. Clin Nucl Med 1995; 20: 703-705.
185. Ishibashi M, Nishida H, Kumabe T, et al. Tc-99m tetrofosmin. A new diagnostic tracer for parathyroid imaging. Clin Nucl Med 1995; 20: 902-905.
186. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
187. Aigner RM, Fueger GF, Nicoletti R, Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies. Eur J Nucl Med 1996; 23: 693-696.
188. Younes A, Songadele JA, Maublant J, Platts E, Pickett R, Veyre A. Mechanism of uptake of technetium tetrofosmin uptake into isolated adult rat heart mitochondria. J Nucl Cardiol 1995; 2: 327-333.
189. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium tetrofosmin uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 1995; 2: 317-326.
190. Songadele JA, Younes A, Maublant J, Veyre A, Platts EA, Pickett RD. Uptake of Tc-99m-tetrofosmin in isolated mitochondria: evidence for an active mechanism [abstract]. J Nucl Med 1994; 35: 46p.
191. Civelek AC, Durski K, Shafique I, et al. Failure of perchlorate to inhibit Tc-99m isonitrile binding by the thyroid during myocardial perfusion studies [see comments]. Clin Nucl Med 1991; 16: 358-361.
192. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37: 1578-1582.
193. 99mTc-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996; 23: 1361-1366.
194. Kawana M, Krizek H, Porter J, Lathrop KA, Charleston D, Harper PV. Use of TI-199 as a potassium analog in scanning [abstract]. J Nucl Med 1970; 11: 333.
195. Lebowitz E, Greene MW, Fairchild R, et al. Thallium-201 for medical use. part 1. J Nucl Med 1975; 16: 151-155.
196. Atkins HL, Budinger TF, Lebowitz E, et al. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J Nucl Med 1977; 18: 133-140.
197. Eck van-Smit BLF, Wall van der EE, Zwinderman AH, Pauwels EKJ. Clinical value of immediate thallium-201 reinjection imaging for the detection of ischemic heart disease. Eur Heart J 1995; 16: 410-420.
198. Cox PH, Belter AJ, van der Pompe WB. Thallium-201 chloride uptake in tumours, a possible complication in heart scintigraphy. Br J Radiology 1976; 49: 767-768.
199. Salvatore M, Carratù L, Bazzicalupo L, Mansi L. The use of Tl-201. Thallium chloride as positive tumour indicator. Eur J Nucl Med 1976; 1:95.
200. 201Tl chloride. Radiology 1978; 129: 497-500.
201. 201Tl uptake in tumours. Eur J Nucl Med 1989; 15: 376-379.
202. Ziada G, Mohammed M, Bahar R. Abdel-Dayem H. Background subtraction in quantitative thallium-201 analysis, normal volunteer study. Nucl Compact 1986; 16: 285-290.
203. +) activated ATP-ase of rabbit kidney. Biochem Biophys Acta 1968; 159: 160-166.
204. 210Tl as a tumour-localising agent: current status and future considerations. Nucl Med Commun 1993; 14: 96-103.
205. Mullins LJ, Moore RD. The movement of thallium ions in muscle. J Gen Physiol 1960; 43: 759-773.
206. Gehring PJ, Hammond PB. The uptake of thallium by rabbit erythrocytes. J Pharmacol Exp Ther 1964; 145: 215-221.
207. Strauss HW, Pitt B. Thallium-201 as a myocardial imaging agent. Semin Nucl Med 1977; 7: 49-58.
208. Sessler M, Maul FD, Geek P, Munz D, Hör G. Kinetics and mechanism of thallium uptake in malignant tumours in vivo and in vitro. In: Raynaud C, ed. 3rd World Congress of Nucl Med and Biol Aug 29 to Sept 2. Paris: Nucl Med and Biol Proceedings. 1982: 2281-2284.
209. 201Tl-chloride. J Nucl Med 1977; 18: 617-625.
210. Senga O, Miyakawa M, Shirota H, et al. Comparison of Tl-201 and Ga-67 citrate scintigraphy in the diagnosis of thyroid tumor: concise communication. J Nucl Med 1982; 23: 225-228.
211. Dudley HC, Maddox GE, La Rue HC. Studies of the metabolism of gallium. J Pharmacol Exp Ther 1949; 96: 135-138.
212. 67Ga citrate. J Nucl Med 1969; 10: 103-105.
213. Hoffer P. Gallium: mechanisms. J Nucl Med 1980; 21: 282-285.
214. Tzen KY, Oster ZH, Wagner HN Jr, Tsan MF. Role of iron-binding proteins and enhanced capillary permeability on the accumulation of gallium-67. J Nucl Med 1980; 21: 31-35.
215. Tsan MF, Scheffel U. Mechanism of gallium-67 accumulation in tumors. J Nucl Med 1986; 27: 1215-1219.
216. Kriegel H. Biokinetics and metabolism of radiogallium. Nuklearmedizin 1984; 23: 53-57.
217. Hartman RE, Hayes RL. The binding of gallium by blood serum. J Pharmacol Exp Ther 1969; 168: 193-198.
218. Gunasekera SW, King LJ, Lavender PJ. The behaviour of tracer gallium-67 towards serum proteins. Clin Chim Acta 1972; 39: 401-406.
219. Hara T. On the binding of gallium to transferrin. Int J Nucl Med Biol 1974; 1: 152-154.
220. Larson SM, Allen DR, Rasey JS, Grunbaum Z. Kinetics of binding of carrier-free Ga-67 to human transferrin. J Nucl Med 1978; 19: 1245-1249.
221. Larson SM, Rasey JS, Allen DR, Nelson NJ. A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. I. Studies in tissue culture. J Nucl Med 1979; 20: 837-842.
222. Vallabhajosula SR, Harwig JF, Siemsen JK, Wolf W. Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med 1980; 21: 650-656.
223. Sephton RG, Harris AW. Gallium-67 citrate uptake by cultured tumor cells stimulated by serum transferrin. J Natl Cancer Inst 1974; 54: 1263-1266.
224. Larson SM, Rasey JS, Allen DR, Grunbaum Z. A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. II. Studies in vivo (BALB/c mice): concise communication. J Nucl Med 1979; 20: 843-846.
225. Chan SM, Hoffer PB, Marie N, Duray P, Yale University School of Medicine NH, CT. Inhibition of Ga-67 uptake in melenonia by an anti-human transferrin receptor monoclonal antibody. J Nucl Med - Proceedings of the 34th annual meeting 1987; 28: 1303-1307.
226. Tsuchiya Y, Nakao A, Komatsu T, Yamamoto M, Shimokata K. Relationship between gallium 67 citrate scanning and transferrin receptor expression in lung diseases. Chest 1992; 102: 530-534.
227. Mizuuchi H, Kudo R, Tamura H, et al. Identification of transferrin receptor in cervical and endometrial tissues. Gynecol Oncol 1988; 31: 292-300.
228. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983; 8323: 498-501.
229. Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990; 416: 491-196.
230. Soyer HP, Smolle J, Smolle-Juettner FM, Kerl H. Proliferation antigens in cutaneous melanocytic tumors - an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen. Dermatologica 1989; 179: 3-9.
231. 67Ga-citrate imaging by iron dextran. J Nucl Med 1976; 17: 356-358.
232. Larson SM, Milder MS, Johnston GS. Interpretation of the 67 Ga photoscan. J Nucl Med 1973; 14: 208-214.
233. Bradley WP, Alderson PO, Eckelman WC, Hamilton RG, Weiss JF. Decreased tumor uptake of gallium-67 in animals after whole-body irradiation. J Nucl Med 1978; 19: 204-209.
234. Hayes RL, Rafter JJ, Byrd BL, Carlton JE. Studies of the in vivo entry of Ga-67 into normal and malignant tissue. J Nucl Med 1981; 22: 325-332.
235. Anghileri LJ. Role of the tumor phospholipids in the accumulation of 67 Ga-citrate. J Nucl Biol Med 1972; 16: 21-23.
236. 67Ga-citrate accumulation by staphylococcal abscesses and by tumors. A common cause: changes in the alkaline-earths metabolism. Nucl Med (Stuttg) 1974; 13: 151-159.
237. 67Ga accumulation. Nucl Med (Stuttg) 1974; 13: 272-276.
238. 67Ga by tumors. Oncology 1977; 34: 74-77.
239. Anghileri LJ. The mechanism of accumulation of radiogallium and radiolanthanides in tumors. J Nucl Biol Med 1973; 17: 177-186.
240. 67Ga citrate. Cancer Res 1976; 36: 452-157.
241. Hoffer PB, Miller-Catschpole R, Turner D. Demonstration of lactoferrin in tumor tissue from two patients with positive gallium scans. J Nucl Med 1979; 20: 424-428.
242. Hoffer PB, Huberty J, Khayam-Bashi H. The association of Ga-67 and lactoferrin. J Nucl Med 1977; 18: 713-717.
243. Larson SM, Rasey JS, Allen DR, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 1980; 64: 41-53.
244. Swartzendruber DC, Nelson B, Hayes RL. Gallium-67 localization in lysosomal-like granules of leukemic and nonleukemic murine tissues. J Natl Cancer Inst 1971; 46: 941-952.
245. 67Ga binding to human serum proteins and tumor components. Cancer Res 1974; 34: 1931-1937.
246. Weiner R, Hoffer PB, Thakur ML. Lactoferrin: its role as a Ga-67-binding protein in polymorphonuclear leukocytes. J Nucl Med 1981; 22: 32-37.
247. Larson SM. Mechanisms of localization of gallium-67 in tumors. Semin Nucl Med 1978; 8: 193-203.
248. 67Ga in normal and malignant animal tissues. Cancer Res 1973; 33: 3265.
249. Larson SM, Rasey JS, Allen DR. The kinetics of uptake and macromolecular binding of Ga-67 and Fe-59 by the EMT-6 sarcoma-like tumor of BALB/c mice. Radiopharmaceuticals 2. Proceedings of the second international symposium on radiopharmaceuticals. New York: Society of Nuclear Medicine: 1979: 297-308.
250. 67Ga localisation in malignant disease. Nucl Med Biol 1996; 23: 745-751.
251. Lavender JP, Lowe J, Barker JR, Burn JI, Chaudri MA. Gallium 67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 1971; 44: 361-366.
252. Tsan MF. Mechanism of gallium-67 accumulation in inflammatory lesions. J Nucl Med 1985; 26: 88-92.
253. Burleson RL, Holman BL, Tow DE. Scintigraphic demonstration of abscesses with radioactive gallium labeled leukocytes. Surg Gynecol Obstet 1975; 141: 379-382.
254. 67Ga to polymorphonuclear leukocytes. Int J Rad Appl Instrum [B] 1987; 14: 523-528.
255. 67Ga incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med 1974; 83: 489-495.
256. Tsan MF. Chen WY, Scheffel U. Studies on gallium accumulation in inflammatory lesions. I. Gallium uptake by human polymorphonuclear leukocytes. J Nucl Med 1978; 19: 36-43.
257. 67Ga in chronic granulocytic leukemia. J Lab Clin Med 1974; 83: 496-503.
258. 67Ga citrate in experimental abscess. Eur J Nucl Med 1979; 20: 1197-1200.
259. Tsan MF. Studies on gallium accumulation in inflammatory lesions. 3. Roles of polymorphonuclear leukocytes and bacteria. J Nucl Med 1978; 19: 492-195.
260. Camargo EE, Wagner HN, Tsan MF. Studies of gallium accumulation in inflammatory lesions. 4. Kinetics of accumulation and role of polymorphonuclear leukocytes in the distribution of gallium in experimental inflammatory exudates. Nuklearmedizin 1979; 18: 147-150.
261. 67Ga in inflammations in the absence of circulating polymorphonuclear leukocytes. J Nucl Med 1978; 19: 292-294.
262. Neilands JB. Microbial envelope proteins related to iron. Annu Rev Microbiol 1982; 36: 285-309.
263. Menon S, Wagner HN Jr, Tsan MF. Studies on gallium accumulation in inflammatory lesions: 2: Uptake by Staphylococcus aureus: concise communication. J Nucl Med 1978; 19: 44-47.
264. Ando A, Nitta K, Ando I. et al. Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med 1990; 17: 21-27.
265. Ballinger JR, Wan Min Kee J, Rauth AM. In vitro an in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996; 37: 1023-1031.
266. Casciari JJ, Rasey JS. Determination of the radiobiologically hypoxic fraction in multicellular spheroids from data on the uptake of [H 3] fluoromisonidazole. Radiat Res 1995; 141: 28-36.
267. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]-fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-428.
268. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996; 23: 941-946.
269. Marx JL. Tumors, a mixed hag of cells. Science 1982; 215: 275-277.
270. Klein G, Klein E. Evolution of tumours and the impact of molecular oncology. Nature 1985; 315: 190-195.
271. Saemundsen AK, Purtilo DT, Sakamoto K, et al. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybidization. Cancer Res 1981; 41: 4237-4242.
272. Katsav S, De Baetselier P, Tartakovsky B, Feldman M, Segal S. Alterations in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from nonmetastatic to metastatic cells. J Natl Cancer Inst 1983; 71: 317-324.
273. Dalialis T, Ährlund-Richter L, Merino F, Klein E, Klein G. Reduced humoral and cellular cytotoxic sensitivity in major histocompatibility variants of the YAC(Moloney) lymphoma. Immunogenetics 1981; 12: 371-380.
274. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602.
275. van Denderen J, Hermans A, Meeuwsen T, et al. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 1989; 169: 87-98.
276. Feizi T. Carbohydrate antigens in human cancer. Cancer Surv 1985; 4: 245-69.
277. Hakomori S. Aberrrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985; 45: 2405-2414.
278. Hakomori S. Aberrant glycolysation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257-331.
279. Lloyd KO. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Am J Clin Pathol 1987; 87: 129-139.
280. Thurin J. Characterisation and molecular biology of tumor-associated antigens. Cnrr Opin Immunol 1990; 2: 702-707.
281. Hakomori S. Tumor-associated carbohydrate antigens. Ann Rev Immunol 1984; 2: 103-126.
282. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43: 1072-1076.
283. Yamashita Y, Chung YS, Horie R, Kannagi R, Sowa M. Alterations in gastric mucin with malignant transformation: novel pathway for mucin synthesis. J Natl Cancer Inst 1995; 87: 441-446.
284. Fukuda M. Possible roles for tumor associated carbohydrate antigens. Cancer Res 1996; 56: 2237-2244.
285. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803-814.
286. Hazra DK, Britton KE, Lahiri VL, Gupta AK, Khanna P, Saran S. Immunotechnological trends in radioimmunotargeting: from 'magic bullet' to 'smart bomb'. Nucl Med Commun 1995; 16: 66-75.
287. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28: 1358-1362.
288. Kassis AI. Optimizing antibodies for use in nuclear medicine [editorial; comment]. J Nucl Med 1991; 32: 1751-1753.
289. Pimm MV, Durrant LG, Baldwin RW. Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur J Cancer Clin Oncol 1989; 25: 1325-1332.
290. Baum RP, Driever PH, Drahovsky D, Hor G. A rapid method for the determination of human CEA/mouse anti-CEA immune complexes in patients undergoing immunoscintigraphy. Eur J Nucl Med 1989; 15: 321-325.
291. Fischman AJ, Khaw BA, Strauss HW. Quo vadis radioimmune imaging [see comments]. J Nucl Med 1989; 30: 1911-1915.
292. Pimm MV, Baldwin RW. Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities. Eur J Nucl Med 1987; 13: 348-352.
293. Pimm MV, Andrew SM, Baldwin RW. Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy. Nucl Med Commun 1989; 10: 585-593.
294. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with monoclonal F(ab′)2. J Nucl Med 1983; 24: 316-325.
295. Walker KZ, Seymour Munn K, Towson JE, et al. Radioimmunolocalization and selective delivery of radiation in a rat model system: comparison of intact and fragmented antibody. Nucl Med Commun 1988; 9: 517-526.
296. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90: 6444-6448.
297. Ott RJ, Grey LJ, Zivanovic MA. et al. The limitations of the dual radionuclide subtraction technique for the external detection of tumours by radioiodine-labelled antibodies. Br J Radiol 1983; 56: 101-108.
298. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987; 28: 1604-1610.
299. Pimm MV, Gribben SJ. Determination of the immunoreactivity of radiolabelled monoclonal antibody fragments by binding to immobilised anti-idiotypic antibodies. Life Sci 1995; 56: 1401-1406.
300. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991; 51: 6650-6655.
301. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5996.